ISO 10993 Biological Evaluation &
Regulatory Documentation Services
Device-specific documentation and remediation support for EU MDR, FDA, and selected India / CDSCO projects, with adjacent work included only where it strengthens the biological evaluation file.
The active item follows the section you are reading.
Biological Evaluation Documentation
Core ISO 10993 services for BEP, BER, and TRA work, built around the 2025 revision, current FDA expectations, and real submission use.
The Biological Evaluation Plan is the foundational document of any ISO 10993 biocompatibility strategy. It defines the biological evaluation scope, identifies relevant biological hazards, and establishes the endpoint assessment strategy — including test waivers with scientific justification.
I prepare BEPs that comply with ISO 10993-1:2018 and the updated 2025 revision, structured for EU MDR notified body and FDA reviewer requirements. Each BEP is scientifically grounded, not template-filled.
View the dedicated BEP service page Read why contact classification is the first decision that shapes endpoint strategyWhat's Included
Typical Use Cases
The Biological Evaluation Report is the comprehensive scientific document that evaluates all available data — literature, existing biological test data, material equivalence data, and chemical characterization — to reach risk-based biocompatibility conclusions for each biological endpoint.
I write BERs that demonstrate scientific rigor to notified body reviewers and FDA. My background in cytotoxicity research and biomaterial science means I understand the science behind each endpoint and can justify conclusions with depth.
View the dedicated BER service page Read the article on what ISO 10993-5 cytotoxicity testing actually measures Read how BER conclusions should connect back to the ISO 14971 risk-management fileWhat's Included
Typical Use Cases
The Toxicological Risk Assessment evaluates chemical extractables and leachables from device materials and calculates whether patient exposure levels present an acceptable toxicological risk. This is a critical component of modern ISO 10993 biological evaluation, particularly for devices with complex polymers or coatings.
I prepare TRAs using the Analytical Evaluation Threshold (AET) and Threshold of Toxicological Concern (TTC) approaches as defined in ISO 10993-17 and ISO 10993-18, fully aligned with EU MDR and FDA expectations.
View the chemistry support page for ISO 10993-18, extractables, and leachables interpretation Read the detailed article on why TRA now sits at the center of modern biological evaluationWhat's Included
Typical Use Cases
ISO 10993-1:2025 introduced significant changes to the biological evaluation framework, including the lifecycle approach to biological safety and updated requirements for benefit-risk determination. Companies with existing biological evaluation documentation need to assess whether their BEP and BER meet the updated standard.
I perform a structured gap analysis comparing your existing documentation against ISO 10993-1:2025 requirements, identify specific gaps, and provide a remediation plan — or prepare the updated documentation directly.
What's Included
Submission, Remediation & Selected Adjacent Regulatory Support
Submission-ready work for EU MDR, FDA, and selected India / CDSCO scopes, plus adjacent regulatory deliverables where they directly support the biological evaluation and remediation path.
EU MDR Technical File
Biocompatibility Section
Annex I GSPR §10 Compliance
The EU MDR (2017/745) General Safety and Performance Requirement §10 requires manufacturers to demonstrate that devices achieve intended performance while not compromising patient safety due to material properties. Notified bodies closely scrutinize this section.
- GSPR §10 biocompatibility narrative
- BEP and BER integration into Technical File
- Annex II technical documentation structure
- Material composition documentation
- Notified body response support
Notified Body Query
Response Support
Point-by-point CE Mark remediation
When a notified body flags gaps in your BEP, BER, waived endpoints, Annex I GSPR narrative, or materials framing, the response needs to be scientifically clear and directly tied to the Technical File.
- Point-by-point written response package
- Updated BEP, BER, or Technical File sections
- Stronger waiver and residual-risk justification
- Materials and device-context remediation
- Fast support for active review deadlines
FDA 510(k)
Biocompatibility Section
Per FDA biocompatibility guidance (2020, updated 2023)
FDA published revised guidance in 2020 (updated 2023) on use of ISO 10993-1 for biocompatibility evaluation in device submissions. Documentation is structured to support FDA reviewer requirements.
- FDA-aligned biocompatibility summary
- Endpoint assessment table (FDA format)
- Test waiver justifications
- Chemical characterization summary
- FDA query response support
India / CDSCO
Strategy Support
Selected projects under MDR 2017
Independent support for India pathway planning, documentation readiness, and biocompatibility-linked strategy on selected projects. This service is collaboration-backed where India-specific execution depth is required, and it is intentionally narrower than a broad all-CDSCO-services promise.
- Classification and route assessment support
- Documentation readiness and gap review
- Applicable IS/ISO 10993 evidence framing
- Cross-market alignment with EU MDR and FDA work
- Scoped collaboration for India-specific delivery where needed
Clinical Evaluation Report (CER)
EU MDR Annex XIV — Clinical Evaluation
CER support is available selectively where the clinical evaluation is tightly connected to the biological evaluation strategy, literature appraisal, or broader EU MDR remediation scope.
- EU MDR Annex XIV + MEDDEV 2.7/1 Rev.4 informed
- Systematic literature search and appraisal
- Clinical data evaluation
- Benefit-risk determination
- PMCF requirements identification
PMCF & PMS Documentation
Post-Market Clinical Follow-Up
PMCF and PMS support is available for projects where post-market documentation needs to align with an updated biocompatibility rationale, risk file, or notified body remediation path.
- PMCF Plan preparation
- PMCF Report preparation
- PMS Plan structure
- Periodic Safety Update Report (PSUR)
- EU MDR Annex III compliance
Scientific Writing Adjacent to Regulatory Work
Available where literature synthesis, technical writing, or scientific communication directly supports the regulatory and biocompatibility scope.
Peer-Reviewed Manuscript Preparation
Scientific manuscript writing and editing for biomedical journals. Experience with Elsevier (Bioelectrochemistry, 2025) and Wiley (Advanced Sensor Research, 2024).
EnquireSystematic Literature Reviews
PRISMA-structured systematic reviews for biological evaluation reports and clinical evaluation documentation. Comprehensive PubMed, Embase, and Cochrane searching.
EnquireWhite Papers & Technical Reports
White papers, technical summaries, and grant proposals for MedTech R&D programs and regulatory strategy communications.
EnquireDeliverables at a Glance
Ready to Start Your Biological Evaluation?
Request a short scoping call to discuss your device, regulatory target, and timeline. I respond within 24 hours on business days.